Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 13, 2025
- Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases
- Lead target and indication to be announced MY 2025
0.3864
+0.01 (+3.62%)
Find more stocks in the Stock Screener
GBIO Latest News and Analysis
15 days ago - ChartmillGet insights into the top gainers and losers of Friday's after-hours session.The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
